Lori Anne Kunkel Sells $505K of Enliven Therapeutics Inc (ELVN) — SEC Form 4, Jul 08, 2026

Open-Market Net Sale · SEC Form 4

−$504,903

10b5-1 Plan

Equity position changed by -19.3%

Reporting Owner

Lori Anne Kunkel

Director

TXN 2026-07-06 · FILED 2026-07-08

Equity Position 41.9K sh 51,884 → 41,884

Equity Change -19.3% shares held after vs before

Filing Lag 2 business days within 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

Enliven Therapeutics Inc

ELVN CIK 0001672619

Reporting Owner

Name	Relationship
Lori Anne Kunkel CIK 0001536368	Director

Lori Anne Kunkel at Enliven Therapeutics Inc Full insider history

Bought (12 mo) —

Sold (12 mo) $850,254

More from this insider at Enliven Therapeutics Inc

Non-Derivative Securities Transactions

Title	Date	Type	Shares	Price	Net Total	Post-Txn	Ownership
Common StockF1 F2	2026-07-06	S - Sale 10b5-1	4,111 D	$49.98	-$205,482	47,773	Direct
Common StockF1 F3	2026-07-06	S - Sale 10b5-1	5,889 D	$50.84	-$299,421	41,884	Direct

Footnotes (3)

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026 Show more
F2: This transaction was executed in multiple trades at prices ranging from $49.40 to $50.395. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Show more
F3: This transaction was executed in multiple trades at prices ranging from $50.4306 to $51.3752. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Show more

Institutional Holders

Largest by reported value

5%+ Holders · 13D/G 6 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at Enliven Therapeutics Inc

GET /v1/forms/4/0001536368-26-000007 API docs